Sol-Gel acquires Gorlin syndrome drug candidate Patidegib from PellePharm
Sol-Gel Technologies, an Israel-based dermatology company, has acquired patidegib, a Gorlin syndrome drug candidate in phase 3 development, from US-based biotechnology company PellePharm, in a deal worth up to $75 million. Patidegib has breakthrough therapy and orphan drug designations from the US Food and Drug Administration (FDA). With potential market of more than $300 million, […]